Biocon Moving In ‘Expedited Manner’ Towards Biosimilars Approvals After Facility Clearance

Biocon Biologics’ management shared updates regarding their facilities, expansion, and fast upcoming ustekinumab biosimilar launch in the US. Also, Biocon made a final acquisition payment to Viatris, while increasing its stake in the biosimilars business.